

ERYSIPELAS

Introduction

Erysipelas is a superficial cutaneous process, usually restricted to the dermis but with prominent lymphatic involvement.

Usually affects children, infants, and the elderly.

The term comes from the <u>Greek</u> ἐρυσίπελας (*erysípelas*), meaning ''red skin''.





It was referred to as : Saint Anthony's Fire (= ergotism or erysipelas or Herpes zoster)



🔰 Thesaurus.plus

Predisposing factors include

skin lesions (•surgical incisions, • trauma or

abrasions, • dermatologic diseases such as psoriasis, • or local fungal infections),

- venous stasis,
- neurologic disorders,
- diabetes mellitus,
- and alcohol abuse.

Causes & Risk Factors of Erysipelas



Skin rash Underlying Animal or eczema insect bites

Fungal Injuries infections on the skin Cancer



• It is almost always caused by Group A

β-hemolytic streptococci

(Streptococcus pyogenes),

Staphylococcus aureus, including

methicillin-resistant strains (MRSA)

Streptococcus pyogenes

Similar lesions can be caused by streptococci of group C or G. Rarely, group B streptococci or S. aureus may be the cause.



Erysipelas can affect people of all age groups, races, and sex. Some studies showed that erysipelas is more common in females. The incidence of erysipelas has decreased since the development of antibiotics and improved sanitation. Erysipelas can affect all age groups but is most common in the extremes of age. The peak incidence at 60-80 years old.





Pathophysiology

Skin infection spreads through a break in the skin, directly invading the lymphatic system and causing erysipelas.

- Insect bites, stasis ulceration, surgical incisions, and venous insufficiency have been reported as portals of entry to the skin.
- Some risk factors that predispose people to develop erysipelas are obesity, lymphedema, athlete's foot, leg ulcers, eczema, intravenous drug abuse, poorly controlled diabetes, and liver disease.
- Recurrent erysipelas has also been reported, with the infection typically reoccurring in the same site.

Histopathology

This histopathology will reveal significant vascular dilatation, dermal edema and invasion of bacteria into the lymphatics and connective tissue. Blood vessel invasion is rare.



Clinical findings

Erysipelas remains a clinical diagnosis, and assessing a patient for any recent skin trauma or pharyngitis is important.

Patients often experience systemic symptoms, such as malaise, fever, and chills 48 hours before the onset of the skin lesion.

It has been well described that erysipelas presents as an area of skin erythema that is sharply demarcated with raised edges. Often patients will complain of burning, tenderness, and itchiness at the site. More severe disease can present with vesicles, bullae, and even frank necrosis. The location of inflammation is very important. In lower extremity erysipelas, it is recommended to examine the interdigital toe spaces for fissures, scaling, or maceration.

Redness and swelling involving a joint should raise suspicion for other more serious disease processes like septic arthritis.



Erysipelas, is characterized by a bright red appearance of the involved skin, which forms a plateau sharply demarcated from surrounding normal skin . The lesion is warm to the touch, may be tender, and appears shiny and swollen. The skin often has a *peau d'orange* texture, which is thought to reflect involvement of superficial lymphatics; superficial blebs or bullae may form, usually 2–3 days after onset.

The lesion typically develops over a few hours and is associated with fever and chills.

Erysipelas tends to occur on the malar area of the face (often with extension over the bridge of the nose to the contralateral malar region) and the lower extremities. After

one episode, recurrence at the same site—sometimes years later—is not uncommon.

 Begins as a small erythematous patch that progresses to a fiery- red, indurated , tense, and shiny plaque.



• The lesion classically exhibits raised sharply demarcated advancing margins.



• Local signs of inflammation warmth, edema, tenderness are universal.



 Lymphatic involvement often is manifested by overlying skin streaking and regional lymphadenopathy.

 More severe infections may exhibit numerous vesicles and bullae along with petechiae and even frank necrosis.





Diagnosis

- The diagnosis is based on clinical signs of the disease.
- Erysipelas is distinguished clinically from other forms of cutaneous infection by two features: the lesions are raised above the level of the surrounding skin, and there is a clear line of demarcation between involved and uninvolved tissue.

There is often a history of a relevant injury. Tests may reveal:

- Raised white cell count
- Raised C-reactive protein
- Positive blood culture identifying the organism.
- MRI and CT are undertaken in case of deep infection.

Differential diagnosis

- 1) Erythema Annulare Centrifugum- begins as small raised pink-red spot that slowly enlarges and forms a ring shape while the central area flattens and clears. There may be an inner rim of scale.
- 2) Stasis Dermatitis
- 3) Cellulitis
- 4) Erysipeloid of Rosenbach, caused by <u>Erysipelothrix</u> <u>rhusiopathiae</u>, is usually unaccompanied by fever or systemic symptoms. It may occur on the hands of patients who sustain cuts or abrasions while handling fish or meats.











- 1) The most common complications of erysipelas are :
 - abscess
 - gangrene
 - thrombophlebitis .
- 2) Less common complications (<1%) are
- acute glomerulonephritis
- endocarditis
- 🖸 septicemia
- Streptococcal toxic shock syndrome.

TREATMENT OF

ERYSIPELAS



Treatment

General

Cold packs and analgesics to relieve local discomfort Elevation of an infected limb to reduce local swelling Compression stockings Wound care with saline dressings that are frequently changed.



Antibiotics

Oral or intravenous penicillin is the antibiotic of first choice. <u>Erythromycin</u>, roxithromycin or pristinamycin may be used in patients with penicillin allergy. If staphylococcal infection is suspected, a flucloxacillin, clindamycin, cefazoline or erythromycin should be selected.

Vancomycin is used for facial erysipelas caused by <u>MRSA</u> Treatment is usually for 10–14 days



Ethiotropic therapy

- ■1. In primary and recurrent erysipelas penicillin is the antibiotic of choice – 5-6 mln Un in 24 hours IM, mild forms – 7 days, moderate forms – 10 days, severe forms – 12-14 days.
- ■2. In relapsing erysipelas semisynthetic penicillins (ampicillin oxacillin, ampiox, amoxicillin, augmentin etc) - 4 g in 24 hours.
- ■3. In frequently relapsing erysipelas antibiotics of choice ar cephalosporines (1-4 generations) 2-4 g in 24 hours; linkomicin 1,2 2,4 g in 24 hours.
- ■(in persistent relapses 2 course treatment)
- 4. For out-patients macrolides (spiramicin 6 mln IU/24 hours) tetracyclines (doxycycline 0,2 g./24 hours)

Prognosis

The disease prognosis includes:

Spread of infection to other areas of body can occur through the bloodstream (<u>bacteremia</u>),

including septic arthritis. Glomerulonephritis can

follow an episode of streptococcal erysipelas or other skin infection, but not <u>rheumatic fever</u>.

Recurrence of infection: Erysipelas can recur in 18– 30% of cases even after antibiotic treatment.

Lymphatic damage

<u>Necrotizing fasciitis</u>, commonly known as "flesheating" bacterial infection, is a potentially deadly exacerbation of the infection if it spreads to deeper tissue.